Xgenera
Xgenera provides a blood-based cancer screening tool that detects multiple cancers early to improve outcomes. It uses microRNA expression measured in blood and a machine‑learning model to identify the presence and location of cancers across 12 types. The core product, miONCO-Dx, is a multi-cancer early diagnostic test delivered as a SaaS-based service for individuals. The test achieves high sensitivity and specificity and aims to be cost-effective to enable earlier cancer diagnosis. By enabling earlier detection, Xgenera seeks to improve survival and reduce the global cancer burden.
Xgenera
Xgenera provides a blood-based cancer screening tool that detects multiple cancers early to improve outcomes. It uses microRNA expression measured in blood and a machine‑learning model to identify the presence and location of cancers across 12 types. The core product, miONCO-Dx, is a multi-cancer early diagnostic test delivered as a SaaS-based service for individuals. The test achieves high sensitivity and specificity and aims to be cost-effective to enable earlier cancer diagnosis. By enabling earlier detection, Xgenera seeks to improve survival and reduce the global cancer burden.